Ticker
GYRECompany Name
GYRE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Total Assets | Cash and Equivalents | Cash to Assets Ratio |
---|---|---|---|
6/30/2025 | $ 152.65M | $ 36.49M | 23.91% |
3/31/2025 | $ 129.79M | $ 15.04M | 11.59% |
12/31/2024 | $ 125.41M | $ 11.81M | 9.42% |
9/30/2024 | $ 125.24M | $ 15.87M | 12.67% |
6/30/2024 | $ 120.93M | $ 16.1M | 13.31% |
3/31/2024 | $ 122.01M | $ 29.79M | 24.41% |
12/31/2023 | $ 116.54M | $ 33.51M | 28.75% |
9/30/2023 | $ 9.96M | $ 2.23M | 22.36% |
6/30/2023 | $ 12.39M | $ 6.92M | 55.86% |
3/31/2023 | $ 18.75M | $ 8.1M | 43.19% |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for GYRE THERAPEUTICS INC is calculated as follows: CashnEq [ $ 24.92M ] / Assets [ $ 111.8M ]
(=) Cash to Assets [ 22.29% ]
Minimum
Dec 31, 2024
Maximum
Jun 30, 2022
Average
Median
filtered constituents | 3.95K |
---|---|
min | 0% |
max | 40.92% |
average | 9.84% |
median | 6.44% |
std | 9.62% |